Nanoparticles in relation to peptide and protein aggregation

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 899-912

  Zaman, Masihuz ^a   Ahmad, Ejaz ^a   Qadeer, Atiyatul ^a   Rabbani, Gulam ^a   Khan, Rizwan Hasan ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Amyloid formation; Inducer; Inhibitor; Nanoparticle; Nucleation; Toxicity

Indexed keywords

NANOPARTICLE; PEPTIDE NANOPARTICLE; PROTEIN NANOPARTICLE; UNCLASSIFIED DRUG; ALBUMINOID; AMYLOID; METAL NANOPARTICLE; PEPTIDE; PROTEIN AGGREGATE;

ANALYTIC METHOD; BETA SHEET; COMPLEX FORMATION; CONJUGATION; DRUG DELIVERY SYSTEM; NANOANALYSIS; NANOFABRICATION; PEPTIDE AGGREGATION; PEPTIDE AGGREGATION INHIBITION; POLYMERIZATION; PROTEIN AGGREGATION; PROTEIN AGGREGATION INHIBITION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; ANIMAL; CHEMISTRY; HUMAN; NANOMEDICINE; NANOTECHNOLOGY;

ALBUMINS; AMYLOID; ANIMALS; HUMANS; METAL NANOPARTICLES; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PEPTIDES; PROTEIN AGGREGATES;

EID: 84896834061     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S54171     Document Type: Review

References (114)

1. Salata OV. Applications of nanoparticles in biology and medicine. J Nanobiotechnology. 2004;2(1):3.
2. Burke KA, Yates EA, Legleiter J. Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration. Front Neurol. 2013;4:17.
3. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010;17(3/4):101-104.
4. Fink AL. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des. 1998;3(1):R9-R23.
5. Fowler DM, Koulov AV, Balch WE, Kelly JW. Functional amyloid from bacteria to humans. Trends Biochem Sci. 2007;32(5):217-224.
6. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl). 2003;81(11):678-699.
7. Naiki H, Hashimoto N, Suzuki S, Kimura H, Nakakuki K, Gejyo F. Establishment of a kinetic model of dialysis-related amyloid fibril extension in vivo. Amyloid. 1997;4(4):223-232.
8. Goy-López S, Juárez J, Alatorre-Meda M, et al. Physicochemical characteristics of protein-NP bioconjugates: the role of particle curvature and solution conditions on human serum albumin conformation and fibrillogenesis inhibition. Langmuir. 2012;28(24):9113-9126.
9. Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7): 543-557.
10. Hill SE, Miti T, Richmond T, Muschol M. Spatial extent of charge repulsion regulates assembly pathways for lysozyme amyloid fibrils. PLoS One. 2011;6(4):e18171.
11. Raccosta S, Martorana V, Manno M. Thermodynamic versus conformational metastability in fibril-forming lysozyme solutions. J Phys Chem B. 2012;116(40):12078-12087.
12. Manno M, Mauro M, Craparo EF, et al. Kinetics of different processes in human insulin amyloid formation. J Mol Biol. 2007;366(1):258-274.
13. Andersen CB, Yagi H, Manno M, et al. Branching in amyloid fibril growth. Biophys J. 2009;96(4):1529-1536.
14. Knight JD, Miranker AD. Phospholipid catalysis of diabetic amyloid assembly. J Mol Biol. 2004;341(5):1175-1187.
15. Lu JR, Perumal S, Powers ET, Kelly JW, Webster JR, Penfold J. Adsorption of beta-hairpin peptides on the surface of water: a neutron reflection study. J Am Chem Soc. 2003;125(13):3751-3757.
16. Linse S, Cabaleiro-Lago C, Xue WF, et al. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci U S A. 2007;104(21):8691-8696.
17. Wu WH, Sun X, Yu YP, et al. TiO2 nanoparticles promote beta-amyloid fibrillation in vitro. Biochem Biophys Res Commun. 2008;373(2): 315-318.
18. Philo JS, Arakawa T. Mechanisms of protein aggregation. Curr Pharm Biotechnol. 2009;10(4):348-351.
19. Abbasi S, Paul A, Shao W, Prakash S. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment. J Drug Deliv. 2012;2012:686108.
20. Fei L, Perrett S. Effect of nanoparticles on protein folding and fibrillogenesis. Int J Mol Sci. 2009;10(2):646-655.
21. Cabaleiro-Lago C, Szczepankiewicz O, Linse S. The effect of nanoparticles on amyloid aggregation depends on the protein stability and intrinsic aggregation rate. Langmuir. 2012;28(3):1852-1857.
22. Katz E, Willner I. Biomolecule-functionalized carbon nanotubes: applications in nanobioelectronics. Chemphyschem. 2004;5(8): 1084-1104.
23. Pasquasto L, Pengo P, Scrimin P. Biological and biomimetic applications of nanoparticles. In: Rotello VM, editor. Nanoparticles: Building Blocks for Nanotechnology. New York, NY: Springer Science + Business Media, Inc; 2004:251-282.
24. Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomedicine. 2010;5:525-532.
25. Kreuter J. Nanoparticulate systems in drug delivery and targeting. J Drug Target. 1995;3(3):171-173.
26. Delehanty JB, Boeneman K, Bradburne CE, Robertson K, Bongard JE, Medintz IL. Peptides for specific intracellular delivery and targeting of nanoparticles: implications for developing nanoparticle-mediated drug delivery. Ther Deliv. 2010;1(3):411-433.
27. Yao N, Xiao W, Wang X, et al. Discovery of targeting ligands for breast cancer cells using the one-bead-one-compound combinatorial method. J Med Chem. 2009;52(1):126-133.
28. Takahashi T, Mihara H. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation. Acc Chem Res. 2008;41(10):1309-1318.
29. Sato J, Takahashi T, Oshima H, Matsumura S, Mihara H. Design of peptides that form amyloid-like fibrils capturing amyloid beta1-42 peptides. Chemistry. 2007;13(27):7745-7752.
30. Li M, Xu C, Wu L, Ren J, Wang E, Qu X. Self-assembled peptidepolyoxometalate hybrid nanospheres: two in one enhances targeted inhibition of amyloid β-peptide aggregation associated with Alzheimer's disease. Small. 2013;9(20);3455-3461.
31. Jarmuła A, Stepkowski D. The β-sheet breakers and π-stacking. J Pept Sci. 2013;19(6):345-349.
32. Todorova N, Yeung L, Hung A, Yarovsky I. "Janus" cyclic peptides: a new approach to amyloid fibril inhibition? PLoS One. 2013;8(2): e57437.
33. Liu Z, Gao X, Kang T, et al. B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjug Chem. 2013;24(6):997-1007.
34. Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm. 2000;194(1):91-102.
35. Schwick HG, Heide K. Immunochemistry and immunology of collagen and gelatin. Bibl Haematol. 1969;33:111-125.
36. Coester C, Nayyar P, Samuel J. In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation. Eur J Pharm Biopharm. 2006;62(3):306-314.
37. Vandervoort J, Ludwig A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm. 2004;57(2):251-261.
38. Azarmi S, Huang Y, Chen H, et al. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharm Sci. 2006;9(1):124-132.
39. Jahanshahi M, Sanati MH, Babaei Z. Optimization of parameters for the fabrication of gelatin nanoparticles by the Taguchi robust design method. J Appl Stat. 2008;35(12):1345-1353.
40. Kuntworbe N, Al-Kassas R. Design and in vitro haemolytic evaluation of cryptolepine hydrochloride-loaded gelatine nanoparticles as a novel approach for the treatment of malaria. AAPS Pharm Sci Tech. 2012;13(2):568-581.
41. Riche M, Williams TN. Apparent digestible protein, energy and amino acid availability of three plant proteins in Florida pompano, Trachinotus carolinus L. in seawater and low-salinity water. Aquaculture Nutrition. 2009;16(3):223-230.
42. Arangoa MA, Ponchel G, Orecchioni AM, Renedo MJ, Duchêne D, Irache JM. Bioadhesive potential of gliadin nanoparticulate systems. Eur J Pharm Sci. 2000;11(4):333-341.
43. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157(2):168-182.
44. Irache JM, Merodio M, Arnedo A, Camapanero MA, Mirshahi M, Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem. 2005;5(3):293-305.
45. Geny B, Mettauer B, Muan B, et al. Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. J Am Coll Cardiol. 1993;22(4):1193-1198.
46. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8(5): 1038-1044.
47. Jahanshahi M, Babaei Z. Protein nanoparticle: a unique system as drug delivery vehicles. African Journal of Biotechnology. 2008;7(25): 4926-4934.
48. Tauran Y, Brioude A, Coleman AW, Rhimi M, Kim B. Molecular recognition by gold, silver and copper nanoparticles. World J Biol Chem. 2013;4(3):35-63.
49. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887-913.
50. Scheffel U, Rhodes BA, Natarajan TK, Wagner HN. Albumin micro-spheres for study of the reticuloendothelial system. J Nucl Med. 1972;13(7):498-503.
51. Gao ZH, Shukla AJ, Johnson JR, Crowley WR. Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: in vitro evaluation. Pharm Res. 1995;12(6): 857-863.
52. Marty JJ, Oppenheim RC, Speiser P. Nanoparticles a new colloidal drug delivery system. Pharm Acta Helv. 1978;53(1):17-23.
53. Lin W, Coombes AG, Davies MC, Davis SS, Illum L. Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target. 1993;1(3):237-243.
54. Coester CJ, Langer K, van Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation a new preparation method, surface modifications and cell uptake. J Microencapsul. 2000;17(2):187-193.
55. Turkevich J, Stevenson PC, Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc. 1951;11:55-75.
56. Benavente E, Lozano H, González G. Fabrication of copper nanoparticles: advances in synthesis, morphology control, and chemical stability. Recent Pat Nanotechnol. 2013;7(2):108-132.
57. Bae DR, Han WS, Lim JM, et al. Lysine-functionalized silver nanoparticles for visual detection and separation of histidine and histidine-tagged proteins. Langmuir. 2010;26(3):2181-2185.
58. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17(3):247-289.
59. Rao CN, Ramakrishna Matte HS, Voggu R, Govindaraj A. Recent progress in the synthesis of inorganic nanoparticles. Dalton Trans. 2012;41(17):5089-5120.
60. Wei X, Wang W, Chen K. Preparation and characterization of ZnS: Tb,Gd and ZnS: Er,Yb,Gd nanoparticles for bimodal magnetic-fluorescent imaging. Dalton Trans. 2013;42(5):1752-1779.
61. Crespo L, Sanclimens G, Pons M, Giralt E, Royo M, Albericio F. Peptide and amide bond-containing dendrimers. Chem Rev. 2005;105(5): 1663-1681.
62. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res. 1997;14(11):1568-1573.
63. Zauner W, Farrow NA, Haines AM. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J Control Release. 2001;71(1):39-51.
64. Babaei Z, Jahanshahi M, Sanati MH. Fabrication and evaluation of gelatin nanoparticles for delivering of anti-cancer drug. International Journal of Nanoscience and Nanotechnology. 2008;4(1):23-30.
65. Powers KW, Brown SC, Krishna VB, Wasdo SC, Moudgil BM, Roberts SM. Research strategies for safety evaluation of nanomaterials. Part VI. Characterization of nanoscale particles for toxicological evaluation. Toxicol Sci. 2006;90(2):296-303.
66. Brar SK, Verma M. Measurement of nanoparticles by light-scattering techniques. TrAC Trends in Analytical Chemistry. 2011;30(1):4-17.
67. Khlebtsov BN, Khlebtsov NG. On the measurement of gold nanoparticle sizes by the dynamic light scattering method. Colloid Journal. 2011;73(1):118-127.
68. Klang V, Valenta C, Matsko NB. Electron microscopy of pharmaceutical systems. Micron. 2013;44:45-74.
69. Tracy JB, Crowe MC, Parker JF, et al. Electrospray ionization mass spectrometry of uniform and mixed monolayer nanoparticles: Au25[S(CH2)2Ph]18 and Au25[S(CH2)2Ph]18-x(SR)x. J Am Chem Soc. 2007;129(51):16209-16215.
70. Ho CS, Lam CW, Chan MH, et al. Electrospray ionisation mass spectrometry: principles and clinical applications. Clin Biochem Rev. 2003;24(1):3-12.
71. Clogston JD, Patri AK. Zeta potential measurement. Methods Mol Biol. 2011;697:63-70.
72. Vertegel AA, Siegel RW, Dordick JS. Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. Langmuir. 2004;20(16):6800-6807.
73. Sear RP. Nucleation: theory and applications to protein solutions and colloidal suspensions. J Phys Condens Matter. 2007;19(3): 033101.
74. Auer S, Trovato A, Vendruscolo M. A condensation-ordering mechanism in nanoparticle-catalyzed peptide aggregation. PLoS Comput Biol. 2009;5(8):e1000458.
75. Lynch I, Dowson KA. Protein-nanoparticle interactions. Nano Today. 2008;3(1/2):40-47.
76. Nielsen L, Khurana R, Coats A, et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry. 2001;40(20):6036-6046.
77. Colvin VL, Kulinowski KM. Nanoparticles as catalysts for protein fibrillation. Proc Natl Acad Sci U S A. 2007;104(21):8679-8680.
78. Baker SE, Cai W, Lasseter TL, Weidkamp KP, Hamers RJ. Covalently bonded adducts of deoxyribonucleic acid (DNA) oligonucleotides with single-wall carbon nanotubes: synthesis and hybridization. Nano Lett. 2002;2(12):1413-1417.
79. Rocha S, Thünemann AF, Pereira Mdo C, Coelho M, Möhwald H, Brezesinski G. Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide. Biophys Chem. 2008;137(1):35-42.
80. Jones CF, Campbell RA, Brooks AE, et al. Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS Nano. 2012;6(11):9900-9910.
81. Tang Z, Zhang Z, Wang Y, Glotzer SC, Kotov NA. Self-assembly of CdTe nanocrystals into free-floating sheets. Science. 2006;314(5797): 274-278.
82. Bellova A, Bystrenova E, Koneracka M, et al. Effect of Fe(3)O(4) magnetic nanoparticles on lysozyme amyloid aggregation. Nanotechnology. 2010;21(6):065103.
83. LeVine H. Thioflavine T interaction with amyloid β-sheet structures. Amyloid. 1995;2(1):1-6.
84. Arnaudov LN, de Vries R. Thermally induced fibrillar aggregation of hen egg white lysozyme. Biophys J. 2005;88(1):515-526.
85. Heldt CL, Zhang S, Belfort G. Asymmetric amyloid fibril elongation: a new perspective on a symmetric world. Proteins. 2011;79(1):92-98.
86. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333-366.
87. Lee CC, Nayak A, Sethuraman A, Belfort G, McRae GJ. A threestage kinetic model of amyloid fibrillation. Biophys J. 2007;92(10): 3448-3458.
88. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, Dawson KA, Linse S. Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. ACS Chem Neurosci. 2010;1(4):279-287.
89. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, et al. Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J Am Chem Soc. 2008;130(46):15437-15443.
90. Skaat H, Chen R, Grinberg I, Margel S. Engineered polymer nanoparticles containing hydrophobic dipeptide for inhibition of amyloid-β fibrillation. Biomacromolecules. 2012;13(9):2662-2670.
91. Milowska K, Malachowska M, Gabryelak T. PAMAM G4 dendrimers affect the aggregation of α-synuclein. Int J Biol Macromol. 2011;48(5):742-746.
92. Klajnert B, Cortijo-Arellano M, Cladera J, Bryszewska M. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun. 2006;345(1):21-28.
93. Rekas A, Lo V, Gadd GE, Cappai R, Yun SI. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein. Macromol Biosci. 2009;9(3):230-238.
94. Milowska K, Gabryelak T, Bryszewska M, Caminade AM, Majoral JP. Phosphorus-containing dendrimers against α-synuclein fibril formation. Int J Biol Macromol. 2012;50(4):1138-1143.
95. Miura Y, Onogi S, Fukuda T. Syntheses of sulfo-glycodendrimers using click chemistry and their biological evaluation. Molecules. 2012;17(10):11877-11896.
96. Kim JE, Lee M. Fullerene inhibits beta-amyloid peptide aggregation. Biochem Biophys Res Commun. 2003;303(2):576-579.
97. Skaat H, Belfort G, Margel S. Synthesis and characterization of fluorinated magnetic core-shell nanoparticles for inhibition of insulin amyloid fibril formation. Nanotechnology. 2009;20(22):225106.
98. Savolainen K, Alenius H, Norppa H, Pylkkänen L, Tuomi T, Kasper G. Risk assessment of engineered nanomaterials and nanotechnologies a review. Toxicology. 2010;269(2/3):92-104.
99. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622-627.
100. Schrand AM, Rahman MF, Hussain SM, Schlager JJ, Smith DA, Syed AF. Metal-based nanoparticles and their toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(5):544-568.
101. Wang B, Feng WY, Wang TC, et al. Acute toxicity of nano-and micro-scale zinc powder in healthy adult mice. Toxicol Lett. 2006;161(2): 115-123.
102. Rothen-Rutishauser B, Grass RN, Blank F, et al. Direct combination of nanoparticle fabrication and exposure to lung cell cultures in a closed setup as a method to simulate accidental nanoparticle exposure of humans. Environ Sci Technol. 2009;43(7):2634-2640.
103. Loo SC, Moore T, Banik B, Alexis F. Biomedical applications of hydroxyapatite nanoparticles. Curr Pharm Biotechnol. 2010;11(4): 333-342.
104. Trouiller B, Reliene R, Westbrook A, Solaimani P, Schiestl RH. Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice. Cancer Res. 2009;69(22):8784-8789.
105. Park EJ, Yi J, Chung KH, Ryu DY, Choi J, Park K. Oxidative stress and apoptosis induced by titanium dioxide nanoparticles in cultured BEAS-2B cells. Toxicol Lett. 2008;180(3):222-229.
106. Lu S, Duffin R, Poland C, et al. Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation. Environ Health Perspect. 2009;117(2):241-247.
107. Arvizo RR, Miranda OR, Thompson MA, et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010;10(7):2543-2548.
108. Verma A, Uzun O, Hu Y, et al. Surface-structure-regulated cellmembrane penetration by monolayer-protected nanoparticles. Nat Mater. 2008;7(7):588-595.
109. Liu Z, Ren G, Zhang T, Yang Z. Action potential changes associated with the inhibitory effects on voltage-gated sodium current of hippocampal CA1 neurons by silver nanoparticles. Toxicology. 2009;264(3):179-184.
110. Ng KW, Khoo SP, Heng BC, et al. The role of the tumor suppressor p53 pathway in the cellular DNA damage response to zinc oxide nanoparticles. Biomaterials. 2011;32(32):8218-8225.
111. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005;11(12):1306-1313.
112. Soenen SJ, Rivera-Gil P, Montenegro JM, Parak WJ, De Smedt SC, Braeckmans K. Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. Nano Today. 2011;6(5):446-465.
113. Unfried K, Albrecht C, Klotz LO, Von Mikecz A, Grether-Beck S, Schins RPF. Cellular responses to nanoparticles: target structures and mechanisms. Nanotoxicology. 2007;1(1):52-71.
114. Cedervall T, Lynch I, Lindman S, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A. 2007;104(7):2050-2055.